Eloxx Pharmaceuticals, Inc.
ELOX- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001035354
No open-market purchases or sales by Eloxx Pharmaceuticals, Inc. insiders were filed in the last 90 days; 22 institutions reported holding it in 13F filings for Q2 2026, worth $34.7M in total; no superinvestor holds it.
13F holders, Q4 2023
Institutional positions in Eloxx Pharmaceuticals, Inc. as of Dec 31, 2023. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 4
- −14 vs. Q3 2023
- Shares held
- 91.0K
- −429.9K (−82.5%) vs. Q3 2023
- Total value
- $109.0K
- −$2.40M (−95.6%) vs. Q3 2023
- New holders
- 0
- 0 more added
- Sold out
- 14
- 0 more reduced
Compare with Q3 2023: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting ELOX on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 22 | $34.7M |
| Q1 2026 | 0 | $0 |
| Q4 2025 | 0 | $0 |
| Q3 2025 | 0 | $0 |
| Q2 2025 | 0 | $0 |
| Q1 2025 | 0 | $0 |
| Q4 2024 | 0 | $0 |
| Q3 2024 | 1 | $0 |
| Q2 2024 | 1 | $43 |
| Q1 2024 | 1 | $62 |
| Q4 2023 | 4 | $109.0K |
| Q3 2023 | 18 | $2.50M |
| Q2 2023 | 16 | $924.2K |
| Q1 2023 | 19 | $671.5K |
| Q4 2022 | 19 | $476.7K |
| Q3 2022 | 32 | $2.14M |
| Q2 2022 | 32 | $3.51M |
| Q1 2022 | 36 | $8.42M |
| Q4 2021 | 39 | $11.7M |
| Q3 2021 | 41 | $26.0M |
| Q2 2021 | 47 | $33.2M |
| Q1 2021 | 38 | $28.7M |
Institutions, Q4 2023
Shares, value and share of portfolio for each institution holding Eloxx Pharmaceuticals, Inc.; share changes are against Q3 2023.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Menora Mivtachim Holdings Ltd. | 52,355 | $62.8K | 0.00% | 00.0% | Unchanged |
| Altshuler Shaham Ltd | 25,123 | $30.1K | 0.00% | 00.0% | Unchanged |
| Clal Insurance Enterprises Holdings Ltd | 13,526 | $16.0K | 0.00% | 00.0% | Unchanged |
| Meeder Asset Management Inc | 15 | $18 | 0.00% | 00.0% | Unchanged |
| Armistice Capital, LLC | 0 | $0 | 0.00% | −275,000−100.0% | Sold out |
| Silverarc Capital Management, LLC | 0 | $0 | 0.00% | −54,075−100.0% | Sold out |
| American Financial Group Inc | 0 | $0 | 0.00% | −37,000−100.0% | Sold out |
| Vanguard Group Inc | 0 | $0 | 0.00% | −20,786−100.0% | Sold out |
| Geode Capital Management, LLC | 0 | $0 | 0.00% | −19,588−100.0% | Sold out |
| Atom Investors LP | 0 | $0 | 0.00% | −10,638−100.0% | Sold out |
| BlackRock Inc. | 0 | $0 | 0.00% | −8,870−100.0% | Sold out |
| Tower Research Capital LLC (TRC) | 0 | $0 | 0.00% | −1,830−100.0% | Sold out |
| Wells Fargo & Company | 0 | $0 | 0.00% | −1,172−100.0% | Sold out |
| Royal Bank of Canada | 0 | $0 | 0.00% | −526−100.0% | Sold out |
| UBS Group AG | 0 | $0 | 0.00% | −291−100.0% | Sold out |
| Morgan Stanley | 0 | $0 | 0.00% | −79−100.0% | Sold out |
| Group One Trading, L.P. | 0 | $0 | 0.00% | −4−100.0% | Sold out |
| JPMorgan Chase & Co | 0 | $0 | 0.00% | −1−100.0% | Sold out |